08Jul
08Jul
FDA Grants Orphan Drug Designation to PBI-200 for NTRK Fusion–Positive Solid Tumors
The FDA has granted an orphan drug designation to PBI-200 for the treatment of patients with NTRK fusion–positive solid tumors, including primary and metastatic brain tumors. PBI-200, which is an oral, highly potent and selective inhibitor of TRK kinase, was designed by Pyramid Biosciences to overcome a wide range of on-target resistance mutations that have been observed with first-generation TRK inhibitors. “Oncogenic NTRK gene fusions are found in a broad range of cancers. Orphan designation for drugs in development such...
01Jul
Top 10 Innovations in Podiatry 2022
Each year, Podiatry Today hears from leaders in the world of foot and ankle medicine and surgery about important developments and significant strides being made in the field. EasyWhip Suture (Winter Innovations) uses a patented two-part needle design to simplify and standardize suture techniques for tendon and ligament reconstruction, according to the company website. Citing speed and quality of stitching as crucial to successful repair, Winter Innovations says EasyWhip is the first suture needle designed to provide both of these...
29Jun
Winning With Talent: Inside Six Boston Tech Companies Hiring Now
Boston is a city of legendary talent. Beantown’s sport legacies, etched along its historic streets, whisper the names of athletes that once called the city home — Brady and Belichick, Bird and Russell, Ruth and Ortiz. Its world-renowned universities have sent recruited emissaries far and wide as intellectual standard-bearers of academic prestige. The fabric of Boston and Cambridge’s historic DNA comprises cutting-edge personnel, weaved together with more than 1,000 biotech companies, from homegrown startups to multinational conglomerates. ...To see how...
29Jun
Vanguard Partners With Candidly For Student Loan Repayment Program
Vanguard has partnered with Candidly to offer retirement plan sponsors a student loan debt repayment program option for eligible employees. The financial wellness service will be available to Vanguard recordkeeping clients as an opt-in feature. Vanguard expects to make the Candidly platform available in the second half of 2022. Workers with student loan debt often have difficulty reaching their financial goals. Financial planning and saving for retirement are complicated, and can be delayed because of student loan debt, says Amber...
29Jun
ZetrOZ Shares Insights for Providers and Patients Seeking Insurance Coverage on Novel Medical Technologies for Advanced Treatments
New medical technologies bring better outcomes to patients and more efficiency to the U.S. healthcare industry, but some insurers and care providers slow its adoption, according to ZetrOZ Systems, a leading innovator and inventor of sustained acoustic medicine for soft tissue injury healing. With more than 100,000 patients treated, George K. Lewis, Ph.D. and CEO of ZetrOZ Systems said, ZetrOZ has learned that a key to winning insurance provider approval of novel medical devices and therapies is thorough advance communication...
29Jun
Vanguard Partners With Candidly For Student Loan Repayment Program
"Vanguard has partnered with Candidly to offer retirement plan sponsors a student loan debt repayment program option for eligible employees. The financial wellness service will be available to Vanguard recordkeeping clients as an opt-in feature. Vanguard expects to make the Candidly platform available in the second half of 2022. Workers with student loan debt often have difficulty reaching their financial goals. Financial planning and saving for retirement are complicated, and can be delayed because of student loan debt, says Amber...
25Jun
Strides Pharma jumps on positive outcome of COVID-19 vaccine trials
Strides Pharma Science rallied 7.70% to Rs 336.50 after the company's subsidiary Biolexis and Akston Biosciences announce encouraging top-line results from phase II/III trial of their thermostable 2nd gen COVID-19 vaccine. The vaccine was well tolerated, with no reported safety issues and is shelf-stable for over six months at room temperature at 25 celsius and potency for one month at 37 celsius. The interim analysis showed 91% seroconversion rate at day 56. The vaccine will be produced at Stelis Biopharma,...
25Jun
Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine
Akston Biosciences Corporation and Biolexis, a Strides Group Company, today announced results from a Phase II/III clinical trial in India of the SARS-CoV-2 vaccine, AKS-452, in which 1,600 healthy volunteers participated – 100 in an open-label bridging study and 1,500 in Phase II/III, double-blind, placebo-controlled trial. An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56. Volunteers in the bridging study had antibody titers that persisted at statistically-significant high levels through...
16Jun